MODERN RADIOTHERAPY REGIMENS AND BIOMARKERS OF RADIORESISTANT RECTAL TUMOR CELLS

Purpose of the study: a review of available data on various modern radiation therapy regimens and their effectiveness, as well as currently known markers of tumor radioresistance. Material and methods. We analyzed relevant publications available in the PubMed and cochrane Library databases between 1984 and 2019, 60 of which were used to write this review. Results. Rectal cancer is one of the most common cancers worldwide. Over the past decade, there has been a significant increase in the incidence of rectal cancer in economically developed countries. In Russia, colorectal cancer is the third most common cancer after lung, gastric and breast cancers. Preoperative radiation therapy followed by surgery is the preferred treatment method for rectal cancer. However, there are cases with no response to preoperative radiation therapy due to tumor cell radioresistance. Various radiotherapy regimens have been developed, differing in their effectiveness: the frequency of local recurrences, overall survival rate and quality of life of patients. cell radioresistance markers are also known. among them, there are genetic markers (changes in gene expression and micro-RNa, mutations) and proteomic markers (changes in protein expression), which can carry not only predictive value, but also be used as targets for therapy. Conclusion. Radioresistance is the major factor leading to the failure of radiotherapy and poor prognosis in patients with rectal cancer. at present, no molecular biomarkers for radiotherapy response prediction are in routine clinical use. Further research is needed to create an effective panel of molecular biomarkers and to improve personalized care for rectal cancer.

rectal cancer, biomarkers, radiation therapy, radioresistance

1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov; 68(6): 394–424. doi: 10.3322/caac.21492.

2. Romano G.M., Bianco F., De Franciscis S., Belli A. The Management of Recurrent Rectal Cancer: A European Perspective. Comprehensive Rectal Cancer Care. Springer, Cham. 2019. p. 521–536. doi: 10.1007/978-3-319-98902-0_27.

3. Glimelius B. Multidisciplinary treatment of patients with rectal cancer: Development during the past decades and plans for the future. Ups J Med Sci. 2012 May; 117(2): 225–36. doi: 10.3109/03009734.2012.658974.

4. Glimelius B. The Swedish Approach. Comprehensive Rectal Cancer Care. Springer, Cham; 2019. p. 335–353. doi: 10.1007/978-3-319-98902-0_19

5. Påhlman L., Glimelius B. Local recurrences after surgical treatment for rectal carcinoma. Acta Chir Scand. 1984; 150(4): 331–5.

6. Swedish Rectal Cancer Trial, Cedermark B., Dahlberg M., Glimelius B., Påhlman L., Rutqvist L.E., Wilking N. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997 Apr 3; 336(14): 980–7. doi: 10.1056/NEJM199704033361402.

7. Lanning R.M., Goodman K.A. Radiation Therapy: The North American Approach. Comprehensive Rectal Cancer Care. Springer, Cham; 2019. P. 365–403. doi: 10.1007/978-3-319-98902-0_21.

8. Bae S.H., Park W., Choi D.H., Nam H., Kang W.K., Park Y.S., Park J.O., Chun H.K., Lee W.Y., Yun S.H., Kim H.C. Palliative radiotherapy in patients with a symptomatic pelvic mass of metastatic colorectal cancer. Radiat Oncol. 2011 May 21; 6: 52. doi: 10.1186/1748-717X-6-52.

9. Sauer R., Liersch T., Merkel S., Fietkau R., Hohenberger W., Hess C., Becker H., Raab H.R., Villanueva M.T., Witzigmann H., Wittekind C., Beissbarth T., Rödel C. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012 Jun 1; 30(16): 1926–33. doi: 10.1200/JCO.2011.40.1836.

10. Cammà C., Giunta M., Fiorica F., Pagliaro L., Craxì A., Cottone M. Preoperative Radiotherapy for Resectable Rectal Cancer: A Meta-analysis. JAMA. 2000; 284(8): 1008–1015. doi:10.1001/jama.284.8.1008.

11. Holman F.A., Bosman S.J., Haddock M.G., Gunderson L.L., Kusters M., Nieuwenhuijzen G.A.P., van den Berg H., Nelson H., Rutten H.J. Results of a pooled analysis of IOERT containing multimodality treatment for locally recurrent rectal cancer: Results of 565 patients of two major treatment centres. Eur J Surg Oncol. 2017 Jan; 43(1): 107–117. doi: 10.1016/j.ejso.2016.08.015.

12. Cai G., Zhu J., Palmer J.D., Xu Y., Hu W., Gu W., Cai S., Zhang Z. CAPIRI-IMRT: a phase II study of concurrent capecitabine and irinotecan with intensity-modulated radiation therapy for the treatment of recurrent rectal cancer. Radiat Oncol. 2015 Feb 28; 10: 57. doi: 10.1186/s13014-015-0360-5.

13. Colorectal Cancer Collaborative Group.Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials. Lancet. 2001; 358(9290): 1291–304. doi: 10.1016/S0140-6736-(01)06409-1.

14. Folkesson J., Birgisson H., Pahlman L., Cedermark B., Glimelius B., Gunnarsson U. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005 Aug 20; 23(24): 5644–50. doi: 10.1200/JCO.2005.08.144.

15. van Gijn W., Marijnen C.A., Nagtegaal I.D., Kranenbarg E.M., Putter H., Wiggers T., Rutten H.J., Påhlman L., Glimelius B., van de Velde C.J.; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011 Jun; 12(6): 575–82. doi: 10.1016/S1470-2045(11)70097-3.

16. Roh M.S., Colangelo L.H., O'Connell M.J., Yothers G., Deutsch M., Allegra C.J., Kahlenberg M.S., Baez-Diaz L., Ursiny C.S., Petrelli N.J., Wolmark N. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol. 2009 Nov 1; 27(31): 5124–30. doi: 10.1200/JCO.2009.22.0467.

17. Martin S.T., Heneghan H.M., Winter D.C. Systematic review and metaanalysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 2012 Jul; 99(7): 918–28. doi: 10.1002/bjs.8702.

18. Glynne-Jones R., Hughes R. Complete response after chemoradiotherapy in rectal cancer (watch-and-wait): have we cracked the code?. Clin Oncol (R Coll Radiol). 2016 Feb; 28(2): 152–160. doi: 10.1016/j.clon.2015.10.011.

19. Langrand-Escure J., Diao P., Garcia M.A., Wang G., Guy J.B., Espenel S., Guillaume E., Rehailia-Blanchard A., Pigné G., de Laroche G., Kaczmarek D., Muron T., Porcheron J., Phelip J.M., Vallard A., Magné N. Outcome and prognostic factors in 593 non-metastatic rectal cancer patients: a mono-institutional survey. Sci Rep. 2018 Jul 16; 8(1): 10708. doi: 10.1038/s41598-018-29040-2.

20. Dayde D., Tanaka I., Jain R., Tai M.C., Taguchi A. Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer. Int J Mol Sci. 2017; 18(3). pii: E573. doi: 10.3390/ijms18030573.

21. You L., Guo X., Huang Y. Correlation of Cancer Stem-Cell Markers OCT4, SOX2, and NANOG with Clinicopathological Features and Prognosis in Operative Patients with Rectal Cancer. Yonsei Med J. 2018 Jan; 59(1): 35–42. doi: 10.3349/ymj.2018.59.1.35.

22. Bowden D.L., Sutton P.A., Wall M.A., Jithesh P.V., Jenkins R.E., Palmer D.H., Goldring C.E., Parsons J.L., Park B.K., Kitteringham N.R., Vimalachandran D. Proteomic profiling of rectal cancer reveals acid ceramidase is implicated in radiation response. J Proteom. 2018; 179: 53–60, doi: 10.1016/j.jprot.2018.02.030.

23. Kim S.C., Shin Y.K., Kim Y.A., Jang S.G., Ku J.L. Identification of genes inducing resistance to ionizing radiation in human rectal cancer cell lines: re-sensitization of radio-resistant rectal cancer cells through down regulating NDRG1. BMC Cancer. 2018; 18(1): 594. doi: 10.1186/s12885-018-4514-3.

24. Bottarelli L., De’ Angelis G.L., Azzoni C., Di Mario F., De’ Angelis N., Leandro G., Fornaroli F., Gaiani F., Negri F. Potential predictive biomarkers in locally advanced rectal cancer treated with preoperative chemo-radiotherapy. Acta Biomed. 2018 Dec 17; 89(9S): 102–106. doi: 10.23750/abm.v89i9-S.7881.

25. Sakai K., Kazama S., Nagai Y., Murono K., Tanaka T., Ishihara S., Sunami E., Tomida S., Nishio K., Watanabe T. Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions. Oncotarget. 2914 Oct 30; 5(20): 9641–9. doi: 10.18632/oncotarget.2438.

26. Martellucci J., Alemanno G., Castiglione F., Bergamini C., Valeri A. Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer. Updates Surg. 2015 Mar; 67(1): 47–53. doi: 10.1007/s13304-015-0281-8.

27. Duldulao M.P., Lee W., Nelson R.A., Li W., Chen Z., Kim J., Garcia-Aguilar J. Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma. Ann Surg Oncol. 2013 Jul; 20(7): 2166–71. doi: 10.1245/s10434-013-2910-0.

28. Kim N.K., Hur H. New Perspectives on Predictive Biomarkers of Tumor Response and Their Clinical Application in Preoperative Chemoradiation Therapy for Rectal Cancer. Yonsei Med J. 2015 Nov; 56(6): 1461–77. doi: 10.3349/ymj.2015.56.6.1461.

29. Azizian A., Gruber J., Ghadimi B.M., Gaedcke J. MicroRNA in rectal cancer. World J Gastrointest Oncol. 2016 May 15; 8(5): 416–26. doi: 10.4251/wjgo.v8.i5.416.

30. Lim S.H., Chua W., Henderson C., Ng W., Shin J.S., Chantrill L., Asghari R., Lee C.S., Spring K.J., de Souza P. Predictive and prognostic biomarkers for neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Crit Rev Oncol Hematol. 2015 Oct; 96(1): 67–80. doi: 10.1016/j.critrevonc.2015.05.003.

31. Conde-Muíño R., Cuadros M., Zambudio N., Segura-Jiménez I., Cano C., Palma P. Predictive Biomarkers to Chemoradiation in Locally Advanced Rectal Cancer. Biomed Res Int. 2015; 2015: 921435. doi: 10.1155/2015/921435.

32. Gaedcke J., Grade M., Camps J., Søkilde R., Kaczkowski B., Schetter A.J., Difilippantonio M.J., Harris C.C., Ghadimi B.M., Møller S., Beissbarth T., Ried T., Litman T. The rectal cancer microRNAome--microRNA expression in rectal cancer and matched normal mucosa. Clin Cancer Res. 2012; 18(18): 4919–30.

33. Campayo M., Navarro A., Benítez J.C., Santasusagna S., Ferrer C., Monzó M., Cirera L. miR-21, miR-99b and miR-375 combination as predictive response signature for preoperative chemoradiotherapy in rectal cancer. PLoS One. 2018 Nov 2; 13(11): e0206542. doi: 10.1371/journal.pone.0206542.

34. Molinari C., Matteucci F., Caroli P., Passardi A. Biomarkers and Molecular Imaging as Predictors of Response to Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer. Clin Colorectal Cancer. 2015 Dec; 14(4): 227–38. doi: 10.1016/j.clcc.2015.05.014.

35. D'Angelo E., Fassan M., Maretto I., Pucciarelli S., Zanon C., Digito M., Rugge M., Nitti D., Agostini M. Serum miR-125b is a noninvasive predictive biomarker of the pre-operative chemoradiotherapy responsiveness in patients with rectal adenocarcinoma. Oncotarget. 2016 May 10; 7(19): 28647–57. doi: 10.18632/oncotarget.8725.

36. Yu J., Li N., Wang X., Ren H., Wang W., Wang S., Song Y., Liu Y., Li Y., Zhou X., Luo A., Liu Z., Jin J. Circulating serum microRNA-345 correlates with unfavorable pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer. Oncotarget. 2016 Sep 27; 7(39): 64233–64243. doi: 10.18632/oncotarget.11649.

37. Li X.F., Jiang Z., Gao Y., Li C.X., Shen B.Z. Combination of three-gene immunohistochemical panel and magnetic resonance imagingdetected extramural vascular invasion to assess prognosis in non-advanced rectal cancer patients. World J Gastroenterol. 2016 Oct 14; 22(38): 8576–8583.

38. Sun W., Li G., Wan J., Zhu J., Shen W., Zhang Z. Circulating tumor cells: A promising marker of predicting tumor response in rectal cancer patients receiving neoadjuvant chemo-radiation therapy. Oncotarget. 2016 Oct 25; 7(43): 69507–69517. doi: 10.18632/oncotarget.10875.

39. Agostini M., Zangrando A., Pastrello C., D’Angelo E., Romano G., Giovannoni R., Giordan M., Maretto I., Bedin C., Zanon C., Digito M., Esposito G., Mescoli C., Lavitrano M., Rizzolio F., Jurisica I., Giordano A., Pucciarelli S., Nitti D. A functional biological network centered on XRCC3: a new possible marker of chemoradiotherapy resistance in rectal cancer patients. Cancer Biol Ther. 2015; 16(8): 1160–71. doi: 10.1080/15384047.2015.1046652.

40. Qin C.J., Song X.M., Chen Z.H., Ren X.Q., Xu K.W., Jing H., He Y.L. XRCC2 as a predictive biomarker for radioresistance in locally advanced rectal cancer patients undergoing preoperative radiotherapy. Oncotarget. 2015 Oct 13; 6(31): 32193–204. doi: 10.18632/oncotarget.4975.

41. Ahmed M.A., Selzer E., Dörr W., Jomrich G., Harpain F., Silberhumer G.R., Müllauer L., Holzmann K., Grasl-Kraupp B., Grusch M., Berger W., Marian B. Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer. Oncotarget. 2016 Oct 25; 7(43): 69976–69990. doi: 10.18632/oncotarget.12099.

42. Voboril R., Rychterova V., Voborilova J., Kubecova M., Fanta J., Dvorak J. NF-κB/p65 expression before and after treatment in rectal cancer patients undergoing neoadjuvant (chemo)radiotherapy and surgery: prognostic marker for disease progression and survival. Neoplasma. 2016; 63(3): 462–70. doi: 10.4149/317_151013N525.

43. Shirota Y., Stoehlmacher J., Brabender J., Xiong Y.P., Uetake H., Danenberg K.D., Groshen S., Tsao-Wei D.D., Danenberg P.V., Lenz H.J. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol. 2001 Dec 1; 19(23): 4298–304. doi: 10.1200/JCO.2001.19.23.4298.

44. Sartore-Bianchi A., Trusolino L., Martino C., Bencardino K., Lonardi S., Bergamo F., Zagonel V., Leone F., Depetris I., Martinelli E., Troiani T., Ciardiello F., Racca P., Bertotti A., Siravegna G., Torri V., Amatu A., Ghezzi S., Marrapese G., Palmeri L., Valtorta E., Cassingena A., Lauricella C., Vanzulli A., Regge D., Veronese S., Comoglio P.M., Bardelli A., Marsoni S., Siena S. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016; 17(6): 738–746. doi: 10.1016/S1470-2045(16)00150-9.

45. Li Y., Liang L., Dai W., Cai G., Xu Y., Li X., Li Q., Cai S. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Mol Cancer. 2016 Aug 24; 15(1): 55. doi: 10.1186/s12943-016-0539-x.

46. Therkildsen C., Bergmann T.K., Henrichsen-Schnack T., Ladelund S., Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta Oncol. 2014 Jul; 53(7): 852–64. doi: 10.3109/0284186X.2014.895036.

47. Karagkounis G., Thai L., DeVecchio J., Gantt G.A., Duraes L., Pai R.K., Kalady M.F. NPTX2 is associated with neoadjuvant therapy response in rectal cancer. J Surg Res. 2016 May 1; 202(1): 112–7. doi: 10.1016/j.jss.2015.12.042.

48. Croner R.S., Sevim M., Metodiev M.V., Jo P., Ghadimi M., Schellerer V., Brunner M., Geppert C., Rau T., Stürzl M., Naschberger E., Matzel K.E., Hohenberger W., Lottspeich F., Kellermann J. Identification of Predictive Markers for Response to Neoadjuvant Chemoradiation in Rectal Carcinomas by Proteomic Isotope Coded Protein Label (ICPL) Analysis. Int J Mol Sci. 2016 Feb 4; 17(2): 209. doi: 10.3390/ijms17020209.

49. Guo Y., Jiang W., Ao L., Song K., Chen H., Guan Q., Gao Q, Cheng J., Liu H., Wang X., Guan G., Guo Z. A qualitative signature for predicting pathological response to neoadjuvant chemoradiation in locally advanced rectal cancers. Radiother Oncol. 2018; 129(1): 149–153. doi: 10.1016/j.radonc.2018.01.010.

50. Lee Y.E., He H.L., Shiue Y.L., Lee S.W., Lin L.C., Wu T.F., Chang I.W., Lee H.H., Li C.F. The prognostic impact of lipid biosynthesis-associated markers, HSD17B2 and HMGCS2, in rectal cancer treated with neoadjuvant concurrent chemoradiotherapy. Tumour Biol. 2015 Sep; 36(10): 7675–83. doi: 10.1007/s13277-015-3503-2.

51. Chai C.Y., Zhang Y., Song J., Lin S.C., Sun S., Chang I.W. VNN1 overexpression is associated with poor response to preoperative chemoradiotherapy and adverse prognosis in patients with rectal cancers. Am J Transl Res. 2016 Oct 15; 8(10): 4455–4463.

52. Chao T.B., Li C.F., Lin C.Y., Tian Y.F., Chang I.W., Sheu M.J., Lee Y.E., Chan T.C., He H.L. Prognostic significance of DSG3 in rectal adenocarcinoma treated with preoperative chemoradiotherapy. Future Oncol. 2016 Jun; 12(12): 1457–67. doi: 10.2217/fon-2016-0071.

53. Ho V., Chung L., Revoltar M., Lim S.H., Tut T.G., Abubakar A., Henderson C.J., Chua W., Ng W., Lee M., De Souza P., Morgan M., Lee C.S., Shin J.S. MRE11 and ATM Expression Levels Predict Rectal Cancer Survival and Their Association with Radiotherapy Response. PLoS One. 2016 Dec 8; 11(12): e0167675. doi: 10.1371/journal.pone.0167675.

54. Cebrián A., Gómez Del Pulgar T., Fernández-Aceñero M.J., Borrero-Palacios A., Del Puerto-Nevado L., Martínez-Useros J., MarínArango J.P., Caramés C., Vega-Bravo R., Rodríguez-Remírez M., Manzarbeitia F., García-Foncillas J. Decreased PLK1 expression denotes therapy resistance and unfavourable disease-free survival in rectal cancer patients receiving neoadjuvant chemoradiotherapy. Pathol Res Pract. 2016 Dec; 212(12): 1133–1137. doi: 10.1016/j.prp.2016.09.012.

55. Zhu K., Zhao Q., Yue J., Shi P., Yan H., Xu X., Wang R. GOLPH3 overexpression correlates with poor response to neoadjuvant therapy and prognosis in locally advanced rectal cancer. Oncotarget. 2016 Oct 18; 7(42): 68328–68338. doi: 10.18632/oncotarget.12008.

56. Yan R., Zhu K., Dang C., Lan K., Wang H., Yuan D., Chen W., Meltzer S.J., Li K. Paf15 expression correlates with rectal cancer prognosis, cell proliferation and radiation response. Oncotarget. 2016 Oct 18; 7(42): 68328–68338. doi: 10.18632/oncotarget.12008.

57. Zaanan A., Park J.M., Tougeron D., Huang S., Wu T.T., Foster N.R., Sinicrope F.A. Association of beclin 1 expression with response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal carcinoma. Int J Cancer. 2015 Sep 15; 137(6): 1498–502. doi: 10.1002/ijc.29496.

58. Del Puerto-Nevado L., Marin-Arango J.P., Fernandez-Aceñero M.J., Arroyo-Manzano D., Martinez-Useros J., Borrero-Palacios A., RodriguezRemirez M., Cebrian A., Gomez Del Pulgar T., Cruz-Ramos M., Carames C., Lopez-Botet B., Garcia-Foncillas J. Predictive value of vrk 1 and 2 for rectal adenocarcinoma response to neoadjuvant chemoradiation therapy: a retrospective observational cohort study. BMC Cancer. 2016 Jul 25; 16: 519. doi: 10.1186/s12885-016-2574-9.

59. Gómez Del Pulgar T., Cebrián A., Fernández-Aceñero M.J., Borrero-Palacios A., Del Puerto-Nevado L., Martínez-Useros J., MarínArango J.P., Caramés C., Vega-Bravo R., Rodríguez-Remírez M., CruzRamos M., Manzarbeitia F., García-Foncillas J. Focal adhesion kinase: predictor of tumour response and risk factor for recurrence after neoadjuvant chemoradiation in rectal cancer. J Cell Mol Med. 2016 Sep; 20(9): 1729–36. doi: 10.1111/jcmm.12879.

60. Peng H., You K., Zhang R., Xi S., Zhang T., Dong J., Cai M., Wang C., Zhang H., Zhou T., Gao Y., Wen B. Predictive value of APAF-1 and COX-2 expression in pathologic complete response to neoadjuvant chemoradiotherapy for patients with locally advanced rectal adenocarcinoma. Oncotarget. 2016 Jun 7; 7(23): 35233–40. doi: 10.18632/oncotarget.9125.